Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy
| العنوان: | Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy |
|---|---|
| المؤلفون: | Gabriela M. Baerlocher, Jasmin Stettler, Thomas Pabst, Katja Seipel, Urban Novak, Behrouz Mansouri Taleghani |
| المصدر: | Stettler, Jasmin; Novak, Urban; Baerlocher, Gabriela M.; Seipel, Katja; Mansouri Taleghani, Behrouz; Pabst, Thomas (2017). Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy. Leukemia & lymphoma, 58(5), pp. 1076-1083. Informa Healthcare 10.1080/10428194.2016.1233542 <http://dx.doi.org/10.1080/10428194.2016.1233542Test> |
| بيانات النشر: | Informa UK Limited, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, Oncology, Melphalan, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, 610 Medicine & health, Kaplan-Meier Estimate, Transplantation, Autologous, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multiple myeloma, Aged, Neoplasm Staging, Aged, 80 and over, Chemotherapy, business.industry, Platelet recovery, Age Factors, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, medicine.disease, Treatment related mortality, Surgery, Immunoglobulin Isotypes, Treatment Outcome, 030220 oncology & carcinogenesis, Toxicity, Female, Stem cell, Multiple Myeloma, business, Biomarkers, 030215 immunology, medicine.drug |
| الوصف: | Administering high-dose chemotherapy (HDCT) with melphalan to elderly myeloma patients represents a challenge with respect to achieving therapeutic efficacy whilst avoiding significant toxicity. We analyzed safety and efficacy of HDCT in 61 elderly myeloma patients older than 65 years, including 12 patients ≥70 years, and compared them with 237 MM patients below 65 years treated in the same period. We observed no differences in the time until neutrophil recovery, infection rate, and treatment related mortality until 100 days after ASCT. Furthermore, higher age was not associated with inferior progression-free and overall survival at 1 and 2 years after ASCT. However, MM patients older than 70 years had a longer duration of hospitalization (26 vs. 20 days; p= .0001) and a longer time until platelet recovery >20G/L (20 vs. 13 days; p= .0007). Our data suggest that HDCT with ASCT is feasible, safe and effective in MM patients older than 65 years. |
| وصف الملف: | application/pdf |
| تدمد: | 1029-2403 1042-8194 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2815c999de70734988055d204c9e59c2Test https://doi.org/10.1080/10428194.2016.1233542Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2815c999de70734988055d204c9e59c2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10292403 10428194 |
|---|